Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gene Logic has entered into an agreement under which it will seek new therapeutic uses for drug candidates developed by Organon which have previously failed clinical development.
Subscribe to our email newsletter
Upon discovery of potential new therapeutic uses for the compounds, both companies will become equal owners and may decide to jointly develop and commercialize the drug candidate.
Gene Logic will receive a success-based milestone payment for each therapeutic candidate that Organon chooses to enter into clinical development.
Gene Logic's drug repositioning program seeks to find alternative development paths for drug candidates with good safety records that have been deprioritized or discontinued in phase II or phase III clinical trials.
“We believe Gene Logic's program has the potential to find new value in our previously deprioritized drug candidates. Organon continues to seek new technologies to increase our drug research output,” said David Nicholson, executive vice president of Global R&D at Organon.